Anti-Human Akt1
| Code | Size | Price |
|---|
| LEI-A270-20ug | 20 ug | £199.00 |
Quantity:
| LEI-A270-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
PN:A279
Long Description:
Akt1, initially identified as the cellular homolog to the retro-viral oncogene v-Akt,1 is part of the phosphatidyl 3?-kinase (PI3K)-Akt signaling pathway that is activated by diverse cellular stimuli and regulates critical cellular functions such as cell growth, proliferation, and survival.2 Following phosphorylation of the second messenger PIP2 by PI3K, Akt1 translocates to the cell membrane where it is activated by phosphoinositide-dependent kinase (PDK) 1 and PDK2.3 The active Akt1 is then able to phosphorylate and activate its substrates, including those that are important for cell proliferation and survival such as TOR and the Bcl-2 homolog Bad.4 Negative regulation of the PI3K-Akt signaling pathway is mainly accomplished by the lipid phosphatase activity of PTEN which catalyzes the conversion of PIP3 to PIP2, thereby preventing the activation of Akt1. Inactivation of this gene often results in excessive Akt1 activity, often leading to the formation of malignant tumors.
Target:
Akt1
References
1. Bellacosa, A. et al. (1991) Science 254:274 2. Song, G. et al. (2005) J. Cell. Mol. Med. 9:59 3. Alessi, DR. et al. (1996) EMBO J. 15:6541 4. Nave, BT. et al. (1999) Biochem. J. 344:427
Related Products
| Product Name | Product Code | Supplier | Akt1 Blocking Peptide | LEI-A279 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|